Taro Pharmaceutical Industries Stock Forecast, Price & News

+0.37 (+0.49 %)
(As of 05/7/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume16,678 shs
Average Volume28,630 shs
Market Capitalization$2.89 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Year FoundedN/A

Sales & Book Value

Annual Sales$644.77 million
Cash Flow$6.81 per share
Book Value$55.15 per share


Net Income$244.24 million




Market Cap$2.89 billion
Next Earnings Date5/18/2021 (Estimated)


Taro Provides Results for December 31, 2020
Taro Provides Results for December 31, 2020
January 27, 2021 |  finance.yahoo.com
See More Headlines
Taro Pharmaceutical Industries logo

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.


Overall MarketRank

0.87 out of 5 stars

Medical Sector

1163rd out of 2,042 stocks

Pharmaceutical Preparations Industry

514th out of 770 stocks

Analyst Opinion: 1.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

Is Taro Pharmaceutical Industries a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Taro Pharmaceutical Industries stock.
View analyst ratings for Taro Pharmaceutical Industries
or view top-rated stocks.

What stocks does MarketBeat like better than Taro Pharmaceutical Industries?

Wall Street analysts have given Taro Pharmaceutical Industries a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Taro Pharmaceutical Industries wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Tuesday, May 18th 2021.
View our earnings forecast for Taro Pharmaceutical Industries

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) posted its earnings results on Wednesday, January, 27th. The company reported $0.86 EPS for the quarter, missing the Zacks' consensus estimate of $1.01 by $0.15. The business earned $140.15 million during the quarter, compared to analyst estimates of $152.63 million. Taro Pharmaceutical Industries had a negative net margin of 45.94% and a positive trailing twelve-month return on equity of 10.36%.
View Taro Pharmaceutical Industries' earnings history

How has Taro Pharmaceutical Industries' stock been impacted by Coronavirus?

Taro Pharmaceutical Industries' stock was trading at $64.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TARO shares have increased by 17.1% and is now trading at $75.47.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TARO?

1 equities research analysts have issued twelve-month price targets for Taro Pharmaceutical Industries' stock. Their forecasts range from $81.00 to $81.00. On average, they anticipate Taro Pharmaceutical Industries' stock price to reach $81.00 in the next twelve months. This suggests a possible upside of 7.3% from the stock's current price.
View analysts' price targets for Taro Pharmaceutical Industries
or view top-rated stocks among Wall Street analysts.

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the following people:
  • Mr. Uday V. Baldota, CEO & Director (Age 51)
  • Ms. Daphne Yan Huang, VP, CFO & Chief Accounting Officer (Age 50)
  • Mr. Itamar Karsenti, VP & Head of Global Operations (Age 49)
  • Mr. Avi Avramoff, VP and Head of R&D (Age 56)
  • Mr. Itzik Baruch, VP of Technical Services (Age 58)
  • Dr. Roman Kaplan Ph.D., VP of Scientific and Technical Compliance Mang. (Age 74)
  • Mr. William J. Coote, Assistant VP of Bus. Fin. & Investor Relations and Treasurer (Age 66)
  • Mr. Erik Zwicker J.D., VP, Gen. Counsel & Sec. (Age 41)
  • Mr. Ara Aprahamian, VP of Sales & Marketing (Age 53, Pay $616.14k)
  • Ms. Michele Visosky, VP & Head of Human Resource (Age 55)

What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO?

11 employees have rated Taro Pharmaceutical Industries CEO Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among Taro Pharmaceutical Industries' employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Taro Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (0.49%) and CLARET ASSET MANAGEMENT Corp (0.04%).

Which major investors are selling Taro Pharmaceutical Industries stock?

TARO stock was sold by a variety of institutional investors in the last quarter, including CLARET ASSET MANAGEMENT Corp.

Which major investors are buying Taro Pharmaceutical Industries stock?

TARO stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc..

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $75.47.

How much money does Taro Pharmaceutical Industries make?

Taro Pharmaceutical Industries has a market capitalization of $2.89 billion and generates $644.77 million in revenue each year. The company earns $244.24 million in net income (profit) each year or $6.35 on an earnings per share basis.

How many employees does Taro Pharmaceutical Industries have?

Taro Pharmaceutical Industries employs 1,464 workers across the globe.

What is Taro Pharmaceutical Industries' official website?

The official website for Taro Pharmaceutical Industries is www.taro.com.

Where are Taro Pharmaceutical Industries' headquarters?

Taro Pharmaceutical Industries is headquartered at 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 914-345-9000 or via email at [email protected]

This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.